Developing a Differentiated Gene Therapy for Sickle Cell Disease: Key Considerations
Time: 9:00 am
day: Day Two
Details:
- Aligning with regulatory requirements for quality of gene therapies, across CMC & clinical development
- Standing out from both a safety and efficacy perspective
- Developing therapies in a ‘crowded’ market – with respect to gene therapies in development and existing standards of care
